Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
J Clin Sleep Med. 2012 Aug 15;8(4):381-7. doi: 10.5664/jcsm.2028.
Obstructive sleep apnea (OSA) is an important and common comorbidity in patients with chronic kidney disease (CKD). However, few studies have addressed how OSA presents in this patient population and whether it is clinically apparent.
The objectives of this study were to determine if the prevalence and severity of sleep related symptoms distinguished CKD patients with OSA from those without apnea, and whether the clinical presentation of OSA in CKD patients differed from the general OSA population.
One hundred nineteen patients were recruited from outpatient nephrology clinics. All patients completed a sleep history questionnaire, the Epworth Sleepiness Scale (daytime sleepiness, ESS > 10), the Pittsburgh Sleep Quality Index (poor sleep quality, PSQI > 5), and underwent overnight cardiopulmonary monitoring for determination of sleep apnea (respiratory disturbance index ≥ 15). CKD patients with OSA (n = 46) were compared to (1) CKD patients without OSA (n = 73) and (2) OSA patients without CKD (n = 230) who were referred to the sleep centre.
The prevalence of OSA symptoms and PSQI scores did not differ between CKD patients with OSA and CKD patients without apnea. Although the prevalence of daytime sleepiness was higher in CKD patients with OSA compared to CKD patients without apnea (39% vs. 19%, p = 0.033), both daytime sleepiness and other symptoms of sleep apnea were considerably less frequent than in OSA patients without a history of kidney disease.
The presence of OSA in patients with CKD is unlikely to be clinically apparent. Consequently, objective cardiopulmonary monitoring during sleep is required to reliably identify this comorbidity.
阻塞性睡眠呼吸暂停(OSA)是慢性肾脏病(CKD)患者的一种重要且常见的合并症。然而,很少有研究探讨 OSA 在这一患者群体中的表现以及其是否具有临床意义。
本研究旨在确定睡眠相关症状的发生率和严重程度是否能区分合并 OSA 的 CKD 患者和不合并呼吸暂停的 CKD 患者,以及 CKD 患者中 OSA 的临床表现是否与一般 OSA 人群不同。
从门诊肾脏科诊所招募了 119 名患者。所有患者均完成了睡眠史问卷、Epworth 嗜睡量表(白天嗜睡,ESS>10)、匹兹堡睡眠质量指数(睡眠质量差,PSQI>5),并进行了整夜心肺监测以确定睡眠呼吸暂停(呼吸紊乱指数≥15)。将合并 OSA 的 CKD 患者(n=46)与(1)不合并 OSA 的 CKD 患者(n=73)和(2)无肾脏疾病史的 OSA 患者(n=230)进行比较。
合并 OSA 的 CKD 患者和无 OSA 的 CKD 患者的 OSA 症状和 PSQI 评分无差异。尽管合并 OSA 的 CKD 患者白天嗜睡的发生率高于无 OSA 的 CKD 患者(39% vs. 19%,p=0.033),但白天嗜睡和其他 OSA 症状的发生率明显低于无肾脏疾病史的 OSA 患者。
CKD 患者 OSA 的存在不太可能具有临床意义。因此,需要进行睡眠期间的心肺客观监测以可靠地识别这种合并症。